If this is your first visit, be sure to check out the FAQ in HCMA Announcements. You may have to register before you can post: click the register link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below. Your Participation in this message board is strictly voluntary. Information and comments on the message board do not necessarily reflect the feelings, opinions, or positions of the Hypertrophic Cardiomyopathy Association. At no time should participants to this board substitute information within for individual medical advice. The Hypertrophic Cardiomyopathy Association shall not be liable for any information provided herein. All participants in this board should conduct themselves in a professional and respectful manner. Failure to do so will result in suspension or termination. The moderators of the message board working with the HCMA will be responsible for notifying participants if they have violated the rules of conduct for the board. Moderators or HCMA staff may edit any post to ensure it conforms with the rules of the board or may delete it. This community is welcoming to all those with HCM we ask that you remember each user comes to the board with information and a point of view that may differ from that which you hold, respect is critical, please post respectfully. Thank you


No announcement yet.

Is the FDA protecting us???


About the Author


Lisa Salberg Find out more about Lisa Salberg
  • Filter
  • Time
  • Show
Clear All
new posts

  • Is the FDA protecting us???

    FDA expert accuses agency over Vioxx

    Christopher Bowe / Washington November 20, 2004

    'A profound regulatory failure, FDA is incapable of protecting America against another Vioxx'.

    The US is “virtually defenceless” against another scandal such as Vioxx, senators investigating Merck’s withdrawal of its popular painkiller were told yesterday.

    Pharmaceuticals regulation was “broken”, Dr David Graham, a senior Food and Drug Administration safety official, said. The federal agency “let the American people down” by not doing enough to warn of Vioxx’s risks.

    He told the Senate finance committee: “Vioxx is a terrible tragedy and a profound regulatory failure the FDA as it is presently configured is incapable of protecting America against another Vioxx. We are virtually defenceless.”

    Vioxx, widely used to treat arthritis, was pulled from sale six weeks ago amid concerns that prolonged use increased the risk of heart failure.

    Raymond Gilmartin, Merck chief executive, insisted the company had followed a rigorous scientific procedure every step of the way.

    All early reports suggesting a link between Vioxx and cardiovascular problems as early as 1999 had been inconclusive, he said, adding: “My wife was taking Vioxx, using Vioxx, up until the day we withdrew it from the market.”Dr Graham led an agency-sponsored study that estimated Vioxx could have caused at least 28,000 heart attacks or deaths.

    He presented preliminary findings in August, but was attacked by Merck and senior FDA officials. A month later, Merck withdrew Vioxx.

    Dr Gurkirpal Singh, a professor of medicine at Stanford University, said internal documents showed Merck could have known in 1996 of potential heart risks for Vioxx, which was approved in 1999.

    He said Merck tailored clinical trials to stop risky side-effects showing up that company officials said would “kill the drug”.

    Merck, he added, tried to intimidate him after he criticised the company and its refusal to provide data on a key early study. He told the hearing: “I was warned that if I continued in this fashion, there would be serious consequences for me.”

    Dr Graham said the FDA system gave too much power to the agency’s office of new drugs, which not only approves new products but also has to act on issues raised by the office of drug safety.

    “The same group that approved the drug is also responsible for taking regulatory action against it post-marketing. This is an inherent conflict of interest.” Dr Graham also launched a swingeing assault on the FDA’s approach to drug safety, saying it regarded post-marketing safety as an “after-thought”.

    In response to questioning, he listed five drugs on sale he believed presented serious potential risks: AstraZeneca’s Crestor, which lowers cholesterol; Abbott Laboratories’ Meridia, a weight-loss drug; Roche’s Accutane, to fight acne;Pfizer’s painkiller, Bextra; and GlaxoSmithKline’s asthma treatment, Serevent.

    Dr Sandra Kweder, acting director of the FDA’s new drug office, said later she did not share Dr Graham’s concerns on the five drugs, and defended the FDA’s performance. She also said Merck acted responsibly.

    The FDA, she insisted, “worked actively and vigorously with Merck to inform public health professionals of what was known regarding cardiovascular risk with Vioxx, and to pursue further definitive investigations to better define and quantify this risk.”
    Knowledge is power ... Stay informed!
    YOU can make a difference - all you have to do is try!

    Dx age 12 current age 46 and counting!
    lost: 5 family members to HCM (SCD, Stroke, CHF)
    Others diagnosed living with HCM (or gene +) include - daughter, niece, nephew, cousin, sister and many many friends!
    Therapy - ICD (implanted 97, 01, 04 and 11, medication
    Currently not obstructed
    Complications - unnecessary pacemaker and stroke (unrelated to each other)

Today's Birthdays